Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective

Immune checkpoint inhibitors (ICIs) are widely used in lung cancer therapy due to their effectiveness and minimal side effects. However, only a few lung cancer patients benefit from ICI therapy, driving the need to develop alternative biomarkers. Programmed death-ligand 1 (PD-L1) molecules expressed...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Wen-Jia, Zhao, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575173/
https://www.ncbi.nlm.nih.gov/pubmed/32960841
http://dx.doi.org/10.1097/CM9.0000000000001090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575173/
https://www.ncbi.nlm.nih.gov/pubmed/32960841
http://dx.doi.org/10.1097/CM9.0000000000001090

Ejemplares similares